ECSP088511A - Agonistas del receptor del neuropeptido-2 - Google Patents

Agonistas del receptor del neuropeptido-2

Info

Publication number
ECSP088511A
ECSP088511A EC2008008511A ECSP088511A ECSP088511A EC SP088511 A ECSP088511 A EC SP088511A EC 2008008511 A EC2008008511 A EC 2008008511A EC SP088511 A ECSP088511 A EC SP088511A EC SP088511 A ECSP088511 A EC SP088511A
Authority
EC
Ecuador
Prior art keywords
neuropeptido
agonists
receiver agonists
receiver
neuropeptide
Prior art date
Application number
EC2008008511A
Other languages
English (en)
Inventor
Jefferson Wright Tilley
Nader Fotouhi
Waleed Danho
Joseph Swistok
Karin Conde-Knape
George Ehrlich
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Rebecca Anne Taub
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088511A publication Critical patent/ECSP088511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan agonistas del receptor del neuropéptido-2 de fórmula (I): Y' | Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2 (I),así como las sales farmacéuticamente aceptables, derivados y fragmentos del mismo, en el que los sustituyentes son tal y como se describen en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades como, por ejemplo, la obesidad y la diabetes.
EC2008008511A 2005-12-07 2008-06-06 Agonistas del receptor del neuropeptido-2 ECSP088511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30

Publications (1)

Publication Number Publication Date
ECSP088511A true ECSP088511A (es) 2008-07-30

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008511A ECSP088511A (es) 2005-12-07 2008-06-06 Agonistas del receptor del neuropeptido-2

Country Status (18)

Country Link
US (2) US7642244B2 (es)
EP (1) EP1962959B1 (es)
JP (1) JP5000663B2 (es)
KR (1) KR101059602B1 (es)
AR (1) AR057222A1 (es)
AT (1) ATE549350T1 (es)
AU (1) AU2006324076A1 (es)
BR (1) BRPI0619573A2 (es)
CA (1) CA2630649A1 (es)
EC (1) ECSP088511A (es)
ES (1) ES2381497T3 (es)
IL (1) IL191636A (es)
MA (1) MA30142B1 (es)
NO (1) NO20082445L (es)
NZ (1) NZ568772A (es)
RU (2) RU2430108C2 (es)
TW (1) TWI321474B (es)
WO (1) WO2007065808A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
WO2007065808A2 (en) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CA2741921A1 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CA2776302A1 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
CN103282054A (zh) 2011-01-03 2013-09-04 弗·哈夫曼-拉罗切有限公司 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
CA2872184A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
RU2630296C2 (ru) 2012-07-04 2017-09-06 Ф. Хоффманн-Ля Рош Аг Антитела к биотину и способы их применения
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
MX373017B (es) 2014-01-03 2020-04-28 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
EP0692971A4 (en) * 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
MXPA02000927A (es) * 1999-07-28 2003-07-14 Johnson & Johnson Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos.
EP1583549A4 (en) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US20090105122A1 (en) 2003-11-25 2009-04-23 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
WO2007065808A2 (en) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof

Also Published As

Publication number Publication date
EP1962959A2 (en) 2008-09-03
CA2630649A1 (en) 2007-06-14
IL191636A0 (en) 2008-12-29
US8268784B2 (en) 2012-09-18
KR20080082672A (ko) 2008-09-11
WO2007065808A2 (en) 2007-06-14
JP5000663B2 (ja) 2012-08-15
TWI321474B (en) 2010-03-11
NZ568772A (en) 2010-05-28
ES2381497T3 (es) 2012-05-28
RU2430108C2 (ru) 2011-09-27
WO2007065808A3 (en) 2007-08-02
ATE549350T1 (de) 2012-03-15
MA30142B1 (fr) 2009-01-02
KR101059602B1 (ko) 2011-08-25
AU2006324076A1 (en) 2007-06-14
EP1962959B1 (en) 2012-03-14
US20070135351A1 (en) 2007-06-14
RU2008127265A (ru) 2010-01-20
JP2009518349A (ja) 2009-05-07
NO20082445L (no) 2008-09-03
US7642244B2 (en) 2010-01-05
BRPI0619573A2 (pt) 2011-10-04
AR057222A1 (es) 2007-11-21
US20100137223A1 (en) 2010-06-03
IL191636A (en) 2012-10-31
TW200806311A (en) 2008-02-01
RU2011105310A (ru) 2012-08-20

Similar Documents

Publication Publication Date Title
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
GT200600114A (es) Derivados de ciclopropanocarboxamida
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
ECSP109934A (es) Compuesto - 946
PA8577101A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
IN2012DN03042A (es)
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
TW200643013A (en) Pyrazoles
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
CR8270A (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo